Metastases to Bone clinical trials at UCSF

1 in progress, 0 open to eligible people

Showing trials for

  • Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases

    Sorry, not yet accepting patients

    This is a single-institution, phase 2 trial of zanzalintinib plus investigator-choice bone-strengthening agent in patients with metastatic renal cell carcinoma (RCC) with bone metastases whose disease has advanced on 1-3 prior lines of therapy, including at least one immune oncology-based (IO) therapy in the adjuvant or first-line metastatic setting.

    San Francisco, California

Our lead scientists for Metastases to Bone research studies include .

Last updated: